CareFusion (San Diego) reported the signing of a definitive agreement to acquire the Vital Signs (Totowa, New Jersey) division of GE Healthcare (Chalfont, UK) for $500 million.

Svelte Medical Systems (New Providence, New Jersey) reported the enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study.